0001104659-24-100333.txt : 20240916 0001104659-24-100333.hdr.sgml : 20240916 20240916205732 ACCESSION NUMBER: 0001104659-24-100333 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240912 FILED AS OF DATE: 20240916 DATE AS OF CHANGE: 20240916 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ENRIGHT PATRICK G CENTRAL INDEX KEY: 0001253886 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42270 FILM NUMBER: 241302350 MAIL ADDRESS: STREET 1: CO LONGITUDE CAPITAL PARTNERS LLC STREET 2: 800 EL CAMINO REAL, SUITE 220 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zenas BioPharma, Inc. CENTRAL INDEX KEY: 0001953926 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1000 WINTER ST, SUITE 1200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-271-2954 MAIL ADDRESS: STREET 1: 1000 WINTER ST, SUITE 1200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Zenas BioPharma (Cayman) Ltd DATE OF NAME CHANGE: 20221108 4 1 tm2424157-3_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-09-12 0 0001953926 Zenas BioPharma, Inc. ZBIO 0001253886 ENRIGHT PATRICK G C/O ZENAS BIOPHARMA, INC. 1000 WINTER STREET, SUITE 1200 WALTHAM MA 02451 1 0 0 0 0 Common Stock 2024-09-16 4 C 0 723812 A 723812 I See Footnote Common Stock 2024-09-16 4 C 0 1003592 A 1727404 I See Footnote Common Stock 2024-09-16 4 C 0 334530 A 334530 I See Footnote Common Stock 2024-09-16 4 P 0 440000 17.00 A 774530 I See Footnote Series B Convertible Preferred Stock 2024-09-16 4 C 0 6284933 D Common Stock 723812 0 I See Footnote Series C Convertible Preferred Stock 2024-09-16 4 C 0 8714293 D Common Stock 1003592 0 I See Footnote Series C Convertible Preferred Stock 2024-09-16 4 C 0 2904764 D Common Stock 334530 0 I See Footnote Stock Option (Right to Buy) 17.00 2024-09-12 4 A 0 37000 0 A 2034-09-11 Common Stock 37000 37000 D On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Shares held by Longitude Venture Partners IV, L.P. ("LVPIV"). Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. Shares held by LPF. The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service. By: /s/ Chase Jayasekera, Attorney-in-Fact 2024-09-16